Payer+Provider's Health System Review
Assessment of the FDA Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl products.
Diagnostic error as a result of drug–laboratory test interactions.
March 6, 2019
Stonington S, Coffa D. N Engl J Med. 2019;380:701-704.
Read the full post on AHRQ PSNet
